CERO
CERo Therapeutics Holdings Inc
$
0.000
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
1.87M
EV
4.95M
EV/OCF(TTM)
--
P/S(TTM)
--
CERo Therapeutics Holdings, Inc. is an immunotherapy company advancing the development of engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is designed to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what the Company refers to as Chimeric Engulfment Receptor T cells (CER-T). Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand. The Company is initiating clinical trials for its lead product candidate, CER-1236, for hematological malignancies.
Show More
Valuation Metrics
The current forward P/E ratio for CERo Therapeutics Holdings Inc (CERO.O) is -0.02, compared to its 5-year average forward P/E of -0.04. For a more detailed relative valuation and DCF analysis to assess CERo Therapeutics Holdings Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-0.04
Current PE
-0.02
Overvalued PE
0.06
Undervalued PE
-0.15
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.01
Current PS
0.10
Overvalued PS
0.13
Undervalued PS
-0.11
Financials
Annual
Quarterly
FY2025Q2
YoY :
-8.24%
-4.72M
Operating Profit
FY2025Q2
YoY :
+121.24%
-5.42M
Net Income after Tax
FY2025Q2
YoY :
-71.35%
-61.71
EPS - Diluted
FY2025Q2
N/A
Free Cash Flow
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 141.18% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
783.8K
USD
6
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
2
42.6K
Volume
Months
6-9
0
0.0
Volume
Months
0-12
1
79.5K
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areSelling! The selling amount has increased 141.18% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
783.8K
USD
6
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
CERO News & Events
Events Timeline
2025-11-05 (ET)
2025-11-05
08:21:06
Cero Therapeutics Launches Second Cohort in Phase 1 Study of CER-1236
2025-11-04 (ET)
2025-11-04
09:10:09
Cero Therapeutics to showcase CER-1236 data at SITC conference
2025-11-03 (ET)
2025-11-03
08:04:17
Cero Therapeutics Reveals Its Listing on OTC Markets
Sign Up For More Events
Sign Up For More Events
News
4.5
10-30TipRanksThursday's Major Stock Market Highlights: Morning News Summary!
7.0
10-30TipRanksWhat Caused CERo Therapeutics Stock to Plummet 80% Today?
4.0
10-30BenzingaD. Boral Capital Reaffirms Buy Rating on CERo Therapeutics Holdings, Keeps $30 Price Target
Sign Up For More News
People Also Watch
FAQ
What is CERo Therapeutics Holdings Inc (CERO) stock price today?
The current price of CERO is 0 USD — it has decreased -1782.33 % in the last trading day.
What is CERo Therapeutics Holdings Inc (CERO)'s business?
What is the price predicton of CERO Stock?
What is CERo Therapeutics Holdings Inc (CERO)'s revenue for the last quarter?
What is CERo Therapeutics Holdings Inc (CERO)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for CERo Therapeutics Holdings Inc (CERO)'s fundamentals?
How many employees does CERo Therapeutics Holdings Inc (CERO). have?